Extending from the nanoagonist-enhanced T cell priming capacity of DCs, we further measured the activated T cell populations (CD4/CD8 T cells) in tumor tissues and spleens after different treatment via immunofluorescence imaging and flow cytometry (Fig. 7d, e, j and Supplementary Figs. 21, 23, 24). The gene discussed is CD4; the disease is neoplasm.